


FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	0277847	1998-30-0523VUS

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: GRILLO-LOPEZ

Appln. No.: 09/762,587

Filing Date: September 6, 2001

Examiner: M. T. B. Davis Group Art Unit: 1642

Date: December 17, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR					
	BR					
	CR					
	DR					
	ER					
	FR					

FOREIGN PATENT DOCUMENTS



Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
GR					
HR					
IR					
JR					
KR					
LR					

OTHER

MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.
OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with 131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp. 1696-1711.
SR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC C2B8, rituximab), 1998, <i>Ann Hematol</i> Vol. 77, pp. 89-91.

Examiner M. T. B. Davis Date Considered: 02/10/04

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Atty. Dkt. No.	M#	Client Ref.
	0277847	1998-30-0523VUS

**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

Applicant: Antonio GRILLO-LOPEZ	
Appln. No.: 09/762,587	
Filing Date: August 11, 1999	
Examiner: M.T.B. Davis	Group Art Unit: 1642

Date: October 3, 2003 Page 1 of 2

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AS	AR 6,306,393	10/2001	Goldenberg			
J	BR 6,183,744	02/2001	Goldenberg			
J	CR					
	DR					

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS							English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor Name		Enclosed	No	Enclose	No
	ER									
	FR									

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

AS	GR	Witzig et al., "Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma," <i>J Clin Oncol</i> , 2002, 20:2453-2463.			
	HR	Petryk et al., "Hematologic Malignancies," <i>The Oncologist</i> , 2001, 6:317-326.			
	IR	Anderson et al., "Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma," <i>Biochem Soc Trans</i> , 1997, 25:705-708.			
	JR	Colombat et al., "Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation," <i>Blood</i> , 2001, 97:101-106.			
	KR	Coiffier et al., "Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study," <i>Blood</i> , 1998, 92:1927-1932.			
	LR	Endo, [Current status of nuclear medicine in Japan], <i>Gan To Kagaku Ryoho</i> , 1999, 26:744-748. <i>Only examine the abstract which is in English this.</i>			
	MR	Foran et al., "European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma," <i>J Clin Oncol</i> , 2000, 18:317-324.			
	NR	Hainsworth et al., "Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma," <i>Blood</i> , 2000, 95:3052-3056.			
	OR	Maloney et al., "IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma," <i>Blood</i> , 1997, 90:2188-2195.			
	PR	McLaughlin et al., "Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program," <i>J Clin Oncol</i> , 1998, 16:2825-2833.			
J	QR	Piro et al., "Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma," <i>Ann Oncol</i> , 1999 10:655-661. (abstract only)			

RR	Davis et al., "Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab," <i>J Clin Oncol</i> , 1999 17(6):1851-1857.				
SR	Byrd et al., "Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity," <i>J Clin Oncol</i> , 2001, 19(8):2153-2164.				
TR					
UR					
VR					
WR					

Examiner _____ Date Considered: _____

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

